S&P 500
(0.25%) 5 193.47 points
Dow Jones
(0.11%) 38 896 points
Nasdaq
(0.16%) 16 375 points
Oil
(0.32%) $78.73
Gas
(0.23%) $2.20
Gold
(-0.39%) $2 322.00
Silver
(-0.28%) $27.54
Platinum
(2.46%) $988.65
USD/EUR
(0.03%) $0.928
USD/NOK
(0.65%) $10.90
USD/GBP
(0.30%) $0.798
USD/RUB
(-0.07%) $91.28

Aktualne aktualizacje dla ImmunityBio, Inc. [IBRX]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Upcoming Earnings Alert

2 days till quarter result
(bmo 2024-05-09)

Expected move: +/- 11.07%

BUY
55.56%
return 79.02%
SELL
55.56%
return -11.89%
Ostatnio aktualizowano7 geg. 2024 @ 19:59

10.17% $ 8.60

SPRZEDAż 208 min ago

@ $8.32

Wydano: 7 geg. 2024 @ 16:30


Zwrot: 3.41%


Poprzedni sygnał: geg. 6 - 16:56


Poprzedni sygnał: Kupno


Zwrot: -7.04 %

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 19:59):
Our systems believe the stock currently is undervalued by 0.54% compare to its pairs and should correct upwards.
Profile picture for ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems...

Stats
Dzisiejszy wolumen 7.12M
Średni wolumen 7.21M
Kapitalizacja rynkowa 5.82B
EPS $-0.350 ( 2024-03-20 )
Następna data zysków ( $-0.160 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -8.78
ATR14 $0.690 (8.08%)
Insider Trading
Date Person Action Amount type
2024-02-22 Simon Barry J. Buy 159 146 Stock Option (right to buy)
2024-02-22 Simon Barry J. Buy 45 731 Restricted Stock Units
2024-02-22 Lauer Regan J Buy 42 439 Stock Option (right to buy)
2024-02-22 Lauer Regan J Buy 12 195 Restricted Stock Units
2024-02-22 Sachs David C. Buy 424 390 Stock Option (right to buy)
INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 | Sell: 921 083
Korelacja (AI algo v.1.1b): Undervalued: 0.54% $8.59 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: -0.69 (moderate negative)
Krótki: -0.90 (very strong negative)
Signal:(57) Neutral

ImmunityBio, Inc. Korelacja

10 Najbardziej pozytywne korelacje
SIRI0.928
RGF0.928
FGBI0.925
AROW0.921
ALRS0.92
GNTY0.92
CBNK0.915
GSMG0.914
GOOD0.906
ALLK0.906
10 Najbardziej negatywne korelacje
RIVE-0.933
DSEY-0.93
DUOL-0.927
AMPH-0.926
RAM-0.919
INTA-0.919
PLYA-0.918
ALTR-0.91
DAIO-0.909
MLTX-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmunityBio, Inc. Korelacja - Waluta/Towar

The country flag -0.71
( moderate negative )
The country flag -0.67
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.72
( moderate negative )
The country flag 0.15
( neutral )
The country flag 0.57
( weak )

ImmunityBio, Inc. Finanse

Annual 2023
Przychody: $622 000
Zysk brutto: $-17.89M (-2 876.21 %)
EPS: $-1.150
FY 2023
Przychody: $622 000
Zysk brutto: $-17.89M (-2 876.21 %)
EPS: $-1.150
FY 2022
Przychody: $240 000
Zysk brutto: $-23.95M (-9 980.00 %)
EPS: $-1.040
FY 2021
Przychody: $934 000
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej